Jean-Jacques Muyembe-Tamfum & Gilead Sciences

Jean-Jacques Muyembe-Tamfum: Jean-Jacques Muyembe-Tamfum, a Congolese virologist, highlighted that the Bundibugyo strain complicates the response as existing treatments and vaccines are for the Zaire strain.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Jean-Jacques Muyembe-Tamfum: Jean-Jacques Muyembe-Tamfum, director of Congo's National Institute for Biomedical Research (INRB), detailed the botched testing and shipping of samples that delayed the identification of the correct Ebola strain.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Jean-Jacques Muyembe-Tamfum: Jean-Jacques Muyembe-Tamfum>>>, medical director of the India — National Geophysical Research Institute>>>, confirmed an American doctor was among the confirmed cases in Bunia.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.